Literature DB >> 12590620

Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review.

David M Taylor1, Corina Young, Carol Paton.   

Abstract

BACKGROUND: Clozapine is indicated for the treatment of resistant schizophrenia, which is usually defined as failure to respond to adequate trials of 2 antipsychotics. It is thought that only clozapine is likely to be effective in such cases and that other drugs are ineffective. We sought to discover prior patterns of antipsychotic prescribing in schizophrenic patients eventually prescribed clozapine.
METHOD: Prescribing histories were obtained from prescription charts and case notes for all inpatients prescribed clozapine in 4 hospitals in southeast London during April 2001.
RESULTS: 120 patients were identified, of whom 112 had been diagnosed with schizophrenia or schizoaffective disorder and whose data were analyzed. The mean duration of illness was 15.1 years. Subjects had experienced a mean of 9.2 (range, 2-35) episodes of antipsychotic prescription before clozapine was first used, with 5.7 (range, 0-25) episodes constituting adequate trials (drug used at therapeutic dose for 6 weeks). The mean number of different antipsychotics used was 5.5 (range, 1-13), with a mean of 4.0 (range, 0-12) given an adequate trial. Ninety percent of patients (N = 101) had received an atypical antipsychotic before first use of clozapine, and 65% (N = 73) had previously received antipsychotic polypharmacy. The mean maximum theoretical delay in using clozapine was 5.0 years (range, 0-11.1 years). Longer delay was significantly (p <.05) associated with being aged over 30 years at the time of the study, being diagnosed with psychotic illness before the introduction of clozapine, and completing adequate trials of 2 different antipsychotics before the introduction of clozapine or risperidone.
CONCLUSION: Clozapine treatment was quite likely delayed for longer than is clinically desirable. This delay may have important effects on quality of life, clinical outcome, and health resource utilization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590620     DOI: 10.4088/jcp.v64n0107

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  40 in total

Review 1.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

2.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

Authors:  Alp Üçok; Ugur Çıkrıkçılı; Ceylan Ergül; Öznur Tabak; Ada Salaj; Sercan Karabulut; Christoph U Correll
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

Review 3.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

4.  Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Authors:  Amanda J Wheeler; Celia L Feetam; Jeff Harrison
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

5.  Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Authors:  Jimmi Nielsen; Søren Skadhede; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-06-02       Impact factor: 7.853

6.  Patterns of clozapine prescribing in a mental health service in New Zealand.

Authors:  Jeff Harrison; Minna Janlöv; Amanda J Wheeler
Journal:  Pharm World Sci       Date:  2010-06-06

7.  Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams.

Authors:  Tongeji E Tungaraza; Wakil Ahmed; Chinonyelum Chira; Erin Turner; Susan Mayaki; Harpal Singh Nandhra; Tom Edwards; Saeed Farooq
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-01

Review 8.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

10.  Coverage of atypical antipsychotics among medicare drug plans in the state of washington for fiscal year 2007.

Authors:  Chi-Chuan Wang; Jae Kennedy; Lawrence J Cohen; David A Sclar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.